NCT07492680 2026-03-25
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
Clinical Trials
75 trialsNCT06346067 2026-02-27
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Erasca, Inc.
Phase 3 Active not recruiting
NCT04478279 2026-02-09
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
Phase 1/2 Active not recruiting
NCT05588453 2026-01-12
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT00539591 2025-12-23
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT06703398 2025-12-23
MIZAR-003
Shanghai Juncell Therapeutics
Phase 2 Recruiting
NCT06624644 2025-09-10
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Phase 2/3 Recruiting
NCT05512481 2025-03-03
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT01119508 2024-06-06
Ipilimumab + Temozolomide in Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00591370 2023-07-25
Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05106023 2023-06-07
To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma
Fudan University
Phase 2 Unknown
NCT05827770 2023-04-25
The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma
Fudan University
Phase 2 Unknown
NCT00667953 2023-03-30
Study of Temzolomide and Gleevec in Advanced Melanoma
Abramson Cancer Center at Penn Medicine
Phase 1/2 Terminated
NCT00602576 2022-06-14
Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT02288897 2022-01-19
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Provectus Pharmaceuticals
Phase 3 Terminated
NCT04884997 2021-05-13
A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT00961844 2021-02-26
Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma
Oslo University Hospital
Phase 1/2 Terminated
NCT01328535 2020-10-22
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Mayo Clinic
Phase 2 Completed
NCT00505635 2020-09-24
Biochemotherapy With Temozolomide for Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00525031 2020-09-23
Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01590082 2020-09-02
Doxycycline, Temozolomide and Ipilimumab in Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01005472 2020-08-03
Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT04397770 2020-05-21
Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT01704287 2020-05-18
KEYNOTE 002
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01196416 2019-11-18
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00301067 2019-06-04
Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma
Northwestern University
Phase 1/2 Completed
NCT01124734 2019-02-12
High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma
Milton S. Hershey Medical Center
Phase 2 Completed
NCT00527657 2018-11-14
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00804908 2018-06-06
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
AbbVie
Phase 2 Completed
NCT00626405 2018-05-01
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT03435302 2018-02-19
HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
Peking University Cancer Hospital & Institute
Phase 3 Unknown
NCT00526617 2017-11-21
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
AbbVie
Phase 1 Completed
NCT01009515 2017-10-18
Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00715793 2017-10-03
UPCI-07-008
University of Pittsburgh
Phase 1/2 Completed
NCT00521001 2017-08-14
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01067066 2017-07-21
A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00925132 2017-07-02
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
University of Iowa
Phase 1/2 Terminated
NCT00091572 2017-06-06
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01409174 2017-05-31
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00831545 2017-05-09
Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00068666 2016-12-15
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT00724841 2016-07-22
A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT02065466 2016-04-21
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
University of Arizona
Phase 1/2 Withdrawn
NCT00588341 2016-02-01
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00673361 2016-01-13
Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma
Duke University
Phase 2 Terminated
NCT00568451 2015-12-30
Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma
Mayo Clinic
Phase 2 Terminated
NCT00885534 2015-05-06
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01127594 2015-03-09
Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion
Duke University
Phase 1 Completed
NCT00338130 2014-08-13
Randomised Study to Compare the Efficacy of AZD6244 vs TMZ
AstraZeneca
Phase 2 Completed
NCT00003747 2013-09-20
Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1 Unknown